Evidence map›Paper›PMID 30408752›Full record

ArticleRedox biology2019

The manganese(III) porphyrin MnTnHex-2-PyP

Ana Flórido, Nuno Saraiva, Sara Cerqueira, Nuno Almeida, Maddy Parsons, Ines Batinic-Haberle, Joana P Miranda, João G Costa, Guia Carrara, Matilde Castro and 2 more

Open access · goldAbstract read
In one paragraph

Article in Redox biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. MnTnHex-2-PyPAntioxidants (Basel, Switzerland) · 2022
    Article
  11. Article
  12. Redox-Active Molecules as Therapeutic Agents.Antioxidants (Basel, Switzerland) · 2022
    Article
  13. Review
  14. Article
  15. MnTnHex-2-PyPAntioxidants (Basel, Switzerland) · 2021
    Article
  16. Article
  17. Article
  18. LOXL2 Inhibitors and Breast Cancer Progression.Antioxidants (Basel, Switzerland) · 2021
    Review
  19. Review
  20. HOxidative medicine and cellular longevity · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Ana FlóridoCBIOS, Universidade Lusófona Research Center for Biosciences & Health Technologies, Campo Grande 376, Lisboa 1749-024, Portugal; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisboa 1649-003, Portugal.
Nuno SaraivaCBIOS, Universidade Lusófona Research Center for Biosciences & Health Technologies, Campo Grande 376, Lisboa 1749-024, Portugal.
Sara CerqueiraCBIOS, Universidade Lusófona Research Center for Biosciences & Health Technologies, Campo Grande 376, Lisboa 1749-024, Portugal.
Nuno AlmeidaCBIOS, Universidade Lusófona Research Center for Biosciences & Health Technologies, Campo Grande 376, Lisboa 1749-024, Portugal.
Maddy ParsonsRandall Centre for Cell and Molecular Biophysics, King's College London, London SE1 1UL, England, UK.
Ines Batinic-HaberleDepartment of Radiation Oncology, Duke University School of Medicine, Durham, NC, USA.
Joana P MirandaResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisboa 1649-003, Portugal.
João G CostaCBIOS, Universidade Lusófona Research Center for Biosciences & Health Technologies, Campo Grande 376, Lisboa 1749-024, Portugal; Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisboa 1649-003, Portugal.
Guia CarraraDepartment of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.
Matilde CastroResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisboa 1649-003, Portugal.
Nuno G OliveiraResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Professor Gama Pinto, Lisboa 1649-003, Portugal.
Ana S FernandesCBIOS, Universidade Lusófona Research Center for Biosciences & Health Technologies, Campo Grande 376, Lisboa 1749-024, Portugal. Electronic address: ana.fernandes@ulusofona.pt.
University of Lisbon · PTUniversidade Lusófona · PTDuke University · USKing's College London · GBUniversity of Cambridge · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Manganese(III) porphyrins (MnPs) are superoxide dismutase (SOD) mimics with demonstrated beneficial effects in cancer treatment in combination with chemo- and radiotherapy regimens. Despite the ongoing clinical trials, little is known about the effect of MnPs on metastasis, being therefore essential to understand how MnPs affect this process. In the present work, the impact of the MnP MnTnHex-2-PyP

Indexed as

Breast NeoplasmsCell AdhesionCell Adhesion MoleculesCell Line, TumorCell MovementCell SurvivalDoxorubicinFemaleGene Expression RegulationHumansIntracellular SpaceMetalloporphyrinsMolecular StructureNF-kappa BReactive Oxygen SpeciesCell Adhesion MoleculesDoxorubicinMetalloporphyrinsMn(III) ortho-tetrakis(N-hexylpyridinium-2-yl)porphyrinNF-kappa BReactive Oxygen SpeciesCancerCell invasionCell migrationManganese porphyrinsRedox modulationSOD mimics

Identifiers

PMID30408752
PMCPMC6222139
OpenAlexW2898235217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.